Epitalon (epithalon) dosage: the circulated short-course schedule vs. the (missing) standard

“Epitalon dosage” is searched as if there is a settled answer, the way there is for an approved drug. There isn’t. Epitalon — also spelled epithalon, and the same molecule either way: the synthetic tetrapeptide Ala-Glu-Asp-Gly, also written as AEDG^[1] — is not an FDA-approved medicine. It has no Western prescribing label, no dose validated in independent trials, and no quality-controlled product to anchor a number to. This page exists because people are going to look anyway, and the honest thing to do is describe what is actually circulated, where those numbers come from, and why none of them carry the authority a real drug label would. It is a description, not a protocol.

First, the spelling: epitalon and epithalon are the same thing

Before any number, clear up the name, because the two spellings cause real confusion. Epitalonand epithalon refer to one and the same synthetic peptide — the tetrapeptide Ala-Glu-Asp-Gly, frequently abbreviated AEDG.^[1] It is closely related to an older, less-defined pineal-gland extract called epithalamin (the source preparation behind much of the early human work), but epitalon itself is the short, defined synthetic sequence. So “epithalon dosage,” “epitalon dose,” and “AEDG dosing” are all asking about the same molecule. There is no separate, stronger spelling.

Why there is no “standard” dose

A standardized dose is something a molecule earns: it comes from a regulatory approval, a prescribing label, and the dose-finding trials that sit behind them. Epitalon has none of that in the West. What exists instead is a body of older research from a single Russian group — the St. Petersburg Institute of Bioregulation and Gerontology — that administered the peptide (and the epithalamin preparation) in courses and reported effects on the melatonin rhythm,^[2]on lifespan and tumor development in animals,^[3] and on aging markers in elderly subjects.^[4] That literature is the origin of nearly every dosing pattern you’ll see repeated online. We walk through how thin and unreplicated that evidence base is in our epitalon evidence review; the short version is that it was not designed as modern dose-finding work, and it has not been independently confirmed. That is exactly why a confident-sounding “protocol” should be read as a convention, not a validated dose.

The forms you’ll actually encounter

Epitalon is sold almost entirely as an injectable peptide — a lyophilized (freeze-dried) powder in a small vial that the buyer reconstitutes with bacteriostatic water and injects subcutaneously. This is the dominant format and the one nearly all dosing chatter refers to. The most common vial size advertised is the “epithalon 50 mg” vial, and this is where a critical misunderstanding starts: 50 mg is the total amount of peptide powder in the vial, not a single dose. Circulated per-injection amounts are a small fraction of that — so a 50 mg vial is treated as a multi-day or multi-course supply, not one shot. (Nasal sprays and oral/“capsule” versions also circulate, but a peptide this size is poorly absorbed by mouth, and those forms have even less of a basis behind any stated amount.)

Because reconstitution is where most dosing errors and contamination risks happen, anyone reasoning about a vial like this should understand how the math and sterility actually work — our guide to reconstituting peptides explains why a “50 mg” label tells you almost nothing about a per-injection amount on its own.

The circulated “course” pattern, and where it comes from

The single most distinctive thing about epitalon dosing — and the reason the hero image above is a calendar, not a syringe — is that it is described as a short course, not a continuous daily habit. The pattern repeated across sellers and forums is a daily injection for roughly 10 to 20 days, after which the person stops for a long stretch (often months) before considering another course, sometimes framed as one or two courses a year. This “pulse then rest” shape is not arbitrary marketing invention: it echoes how the original research was structured. The Russian studies dosed epithalamin and epitalon in defined courses rather than indefinitely — the melatonin-rhythm and geroprotector reports gave the preparation as repeated short courses in older subjects,^[2][4] and the clinical-studies summaries from the same program describe course-based administration as the norm.^[5]

That lineage is worth naming plainly, because it cuts both ways. On one hand, the cycle structure isn’t something users made up; it traces to how the compound was actually studied. On the other hand, those studies are the same thin, single-source, unreplicated body of work that can’t support the longevity claims in the first place — so inheriting their schedule does not inherit any proof that the schedule works. The short half-life of a small peptide like this is part of the rationale offered for frequent dosing within a course, but a fast-clearing peptide given on an unvalidated schedule is still an unvalidated regimen.

“How much epitalon?” — the honest answer

If the question is “how much epitalon should I take,” the truthful answer is that no one can give you a validated number, because none exists. You can find circulated numbers — a small per-injection amount, daily, for a couple of weeks, once or twice a year — and you now know where their shape comes from. But the precision those numbers imply is false: they are not anchored to a label, a dose-finding trial, or a guaranteed product. Two things are true at once. The schedule is real in the sense that it’s what people do and roughly mirrors the source research; and the schedule is unproven in the sense that the research behind it is too thin, too old, and too single-source to establish that any amount produces the telomerase or longevity effects it’s sold for.^[5]

The supply problem makes the dose problem worse

A dose is only meaningful if you know what’s in the vial. With epitalon, you usually don’t. Because it’s sold as unregulated “research-use-only” material rather than a pharmaceutical product, the identity, purity, actual peptide content, and sterility of a given “50 mg” vial are not verified to any standard. So an unvalidated schedule gets layered on top of a product of unknown content — the two uncertainties multiply rather than cancel. Anyone weighing this despite the weak evidence should at least understand the sourcing hazards first; see where to get peptides safely for what that gray market actually looks like, and our peptide therapy cost breakdown for why the cheap sticker is the part of the transaction that hides the real risk.

A word on safety

There is no controlled long-term human safety dataset for epitalon as it is actually sold — an unregulated injectable used off any label. That absence is its own caution: a self-administered injection of a non-pharmaceutical-grade peptide carries the ordinary risks of any injection (infection, injection-site reactions, contamination from a non-sterile product) plus the unknowns of a compound without modern safety characterization at the doses people use. None of the circulated schedules has been shown safe by current standards. If you are weighing epitalon for any reason, the right move is to talk it through with a qualified clinician who can assess your individual situation — not to lift a number off a vendor page or a forum.

The honest bottom line

Epitalon (epithalon) has no FDA-approved dose, no Western label, and no standardized regimen. What circulates instead is a short-course pattern — a daily injection for about ten to twenty days, then a long off-cycle gap, repeated once or twice a year — and that shape is a real inheritance from the Russian course-based research, not a validated protocol. The ubiquitous “50 mg” vial is a supply, not a dose, and treating it otherwise is the most common error. Every number here is reported, not recommended, because the telomerase and longevity claims the whole schedule is built on rest on a thin, single-group, largely unreplicated evidence base — the full case for which is in our epitalon evidence review. Describing what people do is fair; presenting any of it as a proven, safe dose would not be.